JPH0348904B2 - - Google Patents
Info
- Publication number
- JPH0348904B2 JPH0348904B2 JP57500784A JP50078482A JPH0348904B2 JP H0348904 B2 JPH0348904 B2 JP H0348904B2 JP 57500784 A JP57500784 A JP 57500784A JP 50078482 A JP50078482 A JP 50078482A JP H0348904 B2 JPH0348904 B2 JP H0348904B2
- Authority
- JP
- Japan
- Prior art keywords
- encainide
- formula
- halide
- methoxybenzoyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 11
- PJWPNDMDCLXCOM-UHFFFAOYSA-N encainide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 PJWPNDMDCLXCOM-UHFFFAOYSA-N 0.000 description 11
- 229960001142 encainide Drugs 0.000 description 11
- 239000002904 solvent Substances 0.000 description 6
- -1 2-[2- [2-[(4-methoxybenzoyl)amino]phenyl]ethyl]-1-methyl-1-benzylpiperidinium halide Chemical class 0.000 description 5
- 239000003416 antiarrhythmic agent Substances 0.000 description 5
- 150000004820 halides Chemical group 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- BXIOIUQFBPUANP-UHFFFAOYSA-N 1-benzylpiperidine;hydrobromide Chemical compound Br.C=1C=CC=CC=1CN1CCCCC1 BXIOIUQFBPUANP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical group C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- VOGFBLDDNZRUDZ-UHFFFAOYSA-N n-[2-[2-(1,1-dimethylpiperidin-1-ium-2-yl)ethyl]phenyl]-4-methoxybenzamide;iodide Chemical compound [I-].C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1[N+](C)(C)CCCC1 VOGFBLDDNZRUDZ-UHFFFAOYSA-N 0.000 description 1
- XICNVRJHHCHOGI-UHFFFAOYSA-N n-[2-[2-(1-benzyl-1-methylpiperidin-1-ium-2-yl)ethyl]phenyl]-4-methoxybenzamide;bromide;hydrate Chemical compound O.[Br-].C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1[N+](CC=2C=CC=CC=2)(C)CCCC1 XICNVRJHHCHOGI-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/229,244 US4321386A (en) | 1981-01-28 | 1981-01-28 | Quaternary piperidinium halides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57502216A JPS57502216A (enExample) | 1982-12-16 |
| JPH0348904B2 true JPH0348904B2 (enExample) | 1991-07-25 |
Family
ID=22860396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57500784A Expired - Lifetime JPH0348904B2 (enExample) | 1981-01-28 | 1982-01-27 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4321386A (enExample) |
| JP (1) | JPH0348904B2 (enExample) |
| AR (1) | AR230266A1 (enExample) |
| AT (1) | AT378183B (enExample) |
| AU (1) | AU551523B2 (enExample) |
| BE (1) | BE891938A (enExample) |
| CA (1) | CA1184917A (enExample) |
| CH (1) | CH651021A5 (enExample) |
| DE (1) | DE3223499T1 (enExample) |
| DK (1) | DK156649C (enExample) |
| FI (1) | FI65239C (enExample) |
| GB (1) | GB2100736B (enExample) |
| GR (1) | GR74720B (enExample) |
| IE (1) | IE52420B1 (enExample) |
| IT (1) | IT1147809B (enExample) |
| NL (1) | NL8220049A (enExample) |
| SE (1) | SE435057B (enExample) |
| WO (1) | WO1982002551A1 (enExample) |
| YU (1) | YU43063B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010118055A1 (en) * | 2009-04-09 | 2010-10-14 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| RU2012107457A (ru) | 2009-07-31 | 2013-09-10 | Когнишн Терапьютикс, Инк. | Ингибиторы ухудшения когнитивных способностей |
| SG192596A1 (en) | 2011-02-02 | 2013-09-30 | Cognition Therapeutics Inc | Isolated compounds from turmeric oil and methods of use |
| WO2015116923A1 (en) | 2014-01-31 | 2015-08-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| ES3063712T3 (en) | 2017-05-15 | 2026-04-20 | Cognition Therapeutics Inc | Compositions for treating neurodegenerative diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3037910A (en) * | 1958-04-18 | 1962-06-05 | Burroughs Wellcome Co | Process for treatment of hypertension |
| US3931195A (en) * | 1971-03-03 | 1976-01-06 | Mead Johnson & Company | Substituted piperidines |
| US3917679A (en) * | 1974-04-12 | 1975-11-04 | Lilly Co Eli | Quaternary ammonium salts of N-dialkylaminoalkyl-N-(2-indanyl)anilines |
-
1981
- 1981-01-28 US US06/229,244 patent/US4321386A/en not_active Expired - Lifetime
-
1982
- 1982-01-27 GB GB08220076A patent/GB2100736B/en not_active Expired
- 1982-01-27 WO PCT/US1982/000108 patent/WO1982002551A1/en not_active Ceased
- 1982-01-27 JP JP57500784A patent/JPH0348904B2/ja not_active Expired - Lifetime
- 1982-01-27 AU AU81485/82A patent/AU551523B2/en not_active Ceased
- 1982-01-27 DE DE823223499T patent/DE3223499T1/de active Granted
- 1982-01-27 CH CH5828/82A patent/CH651021A5/de not_active IP Right Cessation
- 1982-01-27 AT AT0900782A patent/AT378183B/de active
- 1982-01-28 IT IT47667/82A patent/IT1147809B/it active
- 1982-01-28 BE BE0/207171A patent/BE891938A/fr not_active IP Right Cessation
- 1982-01-28 AR AR288281A patent/AR230266A1/es active
- 1982-01-28 YU YU197/82A patent/YU43063B/xx unknown
- 1982-01-28 IE IE191/82A patent/IE52420B1/en unknown
- 1982-01-28 CA CA000395068A patent/CA1184917A/en not_active Expired
- 1982-01-28 NL NL8220049A patent/NL8220049A/nl unknown
- 1982-01-28 GR GR67146A patent/GR74720B/el unknown
- 1982-07-08 FI FI822443A patent/FI65239C/fi not_active IP Right Cessation
- 1982-09-27 DK DK429382A patent/DK156649C/da not_active IP Right Cessation
- 1982-09-28 SE SE8205535A patent/SE435057B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IT8247667A0 (it) | 1982-01-28 |
| GB2100736A (en) | 1983-01-06 |
| DK429382A (da) | 1982-09-27 |
| BE891938A (fr) | 1982-07-28 |
| YU43063B (en) | 1989-02-28 |
| AU8148582A (en) | 1982-08-16 |
| IE52420B1 (en) | 1987-10-28 |
| IE820191L (en) | 1982-07-28 |
| SE8205535L (sv) | 1982-09-28 |
| ATA900782A (de) | 1984-11-15 |
| CH651021A5 (de) | 1985-08-30 |
| IT1147809B (it) | 1986-11-26 |
| NL8220049A (nl) | 1982-11-01 |
| DK156649B (da) | 1989-09-18 |
| US4321386A (en) | 1982-03-23 |
| DK156649C (da) | 1990-02-05 |
| SE8205535D0 (sv) | 1982-09-28 |
| GB2100736B (en) | 1985-01-30 |
| FI65239C (fi) | 1984-04-10 |
| AT378183B (de) | 1985-06-25 |
| SE435057B (sv) | 1984-09-03 |
| DE3223499C2 (enExample) | 1989-11-23 |
| AU551523B2 (en) | 1986-05-01 |
| GR74720B (enExample) | 1984-07-10 |
| YU19782A (en) | 1985-04-30 |
| FI822443L (fi) | 1982-07-08 |
| DE3223499T1 (de) | 1983-01-13 |
| FI822443A0 (fi) | 1982-07-08 |
| FI65239B (fi) | 1983-12-30 |
| AR230266A1 (es) | 1984-03-01 |
| WO1982002551A1 (en) | 1982-08-05 |
| JPS57502216A (enExample) | 1982-12-16 |
| CA1184917A (en) | 1985-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3068875B2 (ja) | アミン誘導体、その製造方法、心臓脈管疾患および症状を治療するための医薬 | |
| Burke Jr et al. | Resolution, absolute configuration, and antiarrhythmic properties of the enantiomers of disopyramide, 4-(diisopropylamino)-2-(2-pyridyl)-2-phenylbutyramide | |
| US2704757A (en) | 5-hydroxy-3, 4, 5, 6-tetrahydropyriminines | |
| AU551523B2 (en) | Quaternary piperidinium halides | |
| DE69019489T2 (de) | Diazin-Derivate. | |
| DE69020868T2 (de) | Heterozyklische Verbindungen. | |
| HU191126B (en) | Process for producing new n-imino-pyridinium-betaine derivatives and pharmaceutical compositions containing them as active agents | |
| PL94759B1 (pl) | Sposob wytwarzania nowych n-benzhydrylo-n'-p-hydroksybenzylopiperazyn | |
| NO167286B (no) | Fremgangsmaate for fremstilling av terapeutisk aktive benzotiazepin-derivater. | |
| DK146762B (da) | Analogifremgangsmaade til fremstilling af 2,6-dimethyl-3-methoxycarbonyl-4-(2'-nitrophenyl)-1,4-dihydropyridin-5-carboxylsyreisobutylester | |
| US2914533A (en) | Tertiary-aminoalkyl n-(pyridyl)carbamates and their preparation | |
| JPS63150253A (ja) | 新規な１−アリールオキシン−３−アミノ−２−プロパノール、その製造法及び用途 | |
| NO135590B (enExample) | ||
| JPH04128265A (ja) | Ｋｒｎ２３９１酸付加塩およびその用途 | |
| FR2521137A1 (fr) | Halogenures de piperidinium quaternaire | |
| JPS5827270B2 (ja) | ピリダジニウム化合物の製法 | |
| US2919276A (en) | 17beta bromo-17-desoxyyohimbic acid | |
| KR790001687B1 (ko) | 피리딘 유도체의 제법 | |
| FI59089B (fi) | Foerfarande foer framstaellning av 5-endobensoyloxi-n-(amino-(laegre)alkyl)bicyklo(2,2,1)heptan-2,3-di-endokarboxylsyraimider motverkande oregelbunden hjaertverksamhet | |
| JPS6016414B2 (ja) | エナミン類およびその製造方法 | |
| JPH0314831B2 (enExample) | ||
| JPH08502038A (ja) | 抗高血圧作用を有する１，４−ジヒドロピリジン誘導体およびその製造方法 | |
| JPS5936618B2 (ja) | ３，４−ジヒドロカルボスチリル誘導体 | |
| JPS615076A (ja) | 新規な１，４−ジヒドロピリジン誘導体およびその塩 | |
| CH495323A (de) | Verfahren zur Herstellung von neuen, gemischt substituierten 1-Phenoxy-3-alkylaminopropanolen-(2) |